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Clericuzio-type poikiloderma with neutropenia (PN)
is a rare genodermatosis associated with mutations
in the C16orf57 gene, which codes for the uncharac-
terized protein hMpn1. We show here that, in both
fission yeasts and humans, Mpn1 processes the spli-
ceosomal U6 small nuclear RNA (snRNA) posttran-
scriptionally. In Mpn1-deficient cells, U6 molecules
carry 30 end polyuridine tails that are longer than
those in normal cells and lack a terminal 20,30 cyclic
phosphate group. In mpn1D yeast cells, U6 snRNA
and U4/U6 di-small nuclear RNA protein complex
levels are diminished, leading to precursor mes-
senger RNA splicing defects, which are reverted by
expression of either yeast or human Mpn1 and by
overexpression of U6. Recombinant hMpn1 is a
30-to-50 RNA exonuclease that removes uridines
from U6 30 ends, generating terminal 20,30 cyclic
phosphates in vitro. Finally, U6 degradation rates
increase in mpn1D yeasts and in lymphoblasts
established from individuals affected by PN. Our
data indicate that Mpn1 promotes U6 stability
through 30 end posttranscriptional processing and
implicate alteredU6metabolism as a potential mech-
anism for PN pathogenesis.INTRODUCTION
Clericuzio-type poikiloderma with neutropenia (PN) is an auto-
somal-recessive hereditary disorder characterized by a papular
erythematous rash that starts on the limbs and face during
the first year of life and evolves into diffuse poikiloderma
and pachyonychia, especially of the toenails. PN also features
chronic neutropenia and bone marrow abnormalities, leading
to infections mainly of the respiratory system and eventually to
myelodysplasia associated with the risk of leukemic transforma-
tion (Arnold et al., 2010; Chantorn and Shwayder, 2012; Clericu-
zio et al., 2011; Clericuzio et al., 1991; Colombo et al., 2012;
Concolino et al., 2010; Piard et al., 2012; Tanaka et al., 2010;
Volpi et al., 2010; Walne et al., 2010). To date, 38 PN patientsChave been reported in the literature, and they bear 19 different
mutations in the gene C16orf57 (Arnold et al., 2010; Chantorn
and Shwayder, 2012; Clericuzio et al., 2011; Colombo et al.,
2012; Concolino et al., 2010; Piard et al., 2012; Tanaka et al.,
2010; Volpi et al., 2010; Walne et al., 2010), which encodes
a 247 amino acid protein herein referred to as hMpn1 (for
mutated in PN protein 1). Several PN patients have been
misdiagnosed with dyskeratosis congenita (DC) or Rothmund-
Thomson syndrome (RTS) because of a large overlap of the
clinical manifestations of these syndromes (Colombo et al.,
2012; Walne et al., 2010). Therefore, the screening of DC and
RTS patients of thus-far-unknown genetic origin for mutations
in the C16orf57 gene is expected to rapidly augment the number
of known PN patients in the near future. Although structure
prediction algorithms have assigned hMpn1 to the superfamily
of 2H phosphodiesterases found in bacteria, archaea, and
eukaryotes (Colombo et al., 2012; Mazumder et al., 2002), its
functions remain completely obscure. This superfamily com-
prises at least four families of RNA-modifying enzymes, including
bacterial 20–50 RNA ligases, fungal RNA ligases, plant and yeast
10,20 cyclic nucleotide phosphodiesterases, and mammalian
20,30 cyclic nucleotide phosphodiesterases. Two catalytically
active tetrapeptide motifs (H-X-T/S-X, where X is a hydrophobic
residue) are found in all 2H phosphodiesterase superfamily
members, and they correspond to H120L/S122L and H208L/
S210L sequences in hMpn1 (Colombo et al., 2012; Mazumder
et al., 2002).
In eukaryotes, introns within a precursor messenger RNA
(pre-mRNA) transcript are removed by the spliceosome (for
reviews, see: Valadkhan, 2010; Wahl et al., 2009; Will and
Lu¨hrmann, 2011). A core component of the active spliceosome
is the small nuclear RNA (snRNA) U6, an evolutionarily conserved
noncoding RNA (ncRNA) of approximately 100 bases produced
by RNA polymerase III (RNAPIII). U6 participates in the formation
of the active site of the spliceosome and catalyzes the transes-
terification reactions that occur during splicing. At the onset of
spliceosome assembly, U6 and U4, another spliceosomal
snRNA, associate into a di-snRNA protein complex (U4/U6
di-snRNP) wherein the two transcripts are base paired in a cata-
lytically inactive state. Unwinding of the U4-U6 duplex by the
conserved Brr2p/SNRNP200 helicase and release of U4 convert
the spliceosome into a catalytically active form (for reviews,
see: Valadkhan, 2010; Wahl et al., 2009; Will and Lu¨hrmann,
2011). U6 and U4 molecules previously engaged in a splicingell Reports 2, 855–865, October 25, 2012 ª2012 The Authors 855
cycle can be recycled and reassembled into new U4/U6
di-snRNPs for participation in a new round of splicing. Failure
to recycle U6 leads to impaired U4/U6 di-snRNP assembly and
accumulation of free U4 snRNA in yeast, and this defect can
be rescued by overexpression of U6 snRNA (Chen et al.,
2006). Several factors have been shown to assist U6 recycling,
including members of the evolutionarily conserved nineteen
complex (NTC) and the Sm-like 2–8 (LSm2–8) ring complex
(Achsel et al., 1999; Lygerou et al., 1999).
Newly transcribed U6 contains four template 30 end uridine (U)
residues that are immediately bound by the La antigen (Kunkel
et al., 1986; Rinke and Steitz, 1985; Stefano, 1984), whereas in
mature U4/U6 di-snRNPs, the La antigen is superseded by
the LSm2–8 complex (Achsel et al., 1999; Mayes et al., 1999;
Salgado-Garrido et al., 1999; Se´raphin, 1995; Vidal et al.,
1999). The La-to-LSm exchange is a prerequisite for U4/U6
di-snRNP formation, given that the LSm2–8 complex recruits
the Prp24/p110 RNA-binding protein, which promotes the an-
nealing of U4 and U6 (Bell et al., 2002; Martin-Tumasz et al.,
2011; Pannone et al., 1998; Raghunathan and Guthrie, 1998;
Ryan et al., 2002). U6 snRNA molecules are remarkably hetero-
geneous due to extensive posttranscriptional modification of
their 30 termini. Whereas the large majority of cellular U6 mole-
cules contain a short 30 oligo(U) tail comprising five Us blocked
by a cyclic 20,30 phosphate 30 end group (>p group), a small frac-
tion of U6 (10%) can contain 30 oligo(U) stretches up to 20
nucleotides long terminating with a cis-20,30-diol end group
(-OH) (Lund and Dahlberg, 1992; Rinke and Steitz, 1985; Terns
et al., 1992). The dynamic balance between these two major
forms of U6 is determined by two counteracting enzymatic activ-
ities that elongate and trim U6 oligo(U) tails (Gu et al., 1997; Tazi
et al., 1993; Trippe et al., 2003). The enzyme uridylylating U6 30
end has been identified in humans, and it corresponds to the
terminal uridylyltransferase (TUTase) (Trippe et al., 2006). In
contrast, the nuclease that trims the 30 terminus of U6 has not
yet been isolated, and the functional significance of these struc-
tural variants of U6 remains obscure. Here, we reveal that Mpn1
proteins are evolutionarily conserved 30-to-50 RNA exonucleases
that specifically trim U6 oligo(U) and generate U6 molecules
terminating with >p groups. Mpn1-mediated processing of U6
transcripts prevents their degradation. Our data unveil an unan-
ticipated cellular pathway dictating the fate of U6 molecules and
implicate altered U6 processing as a potential mechanism for PN
pathogenesis.
RESULTS
Deletion ofmpn1+ Leads to a Generalized Pre-mRNA
Splicing Defect and to Diminished U6 Cellular Levels in
Fission Yeast
While screening a complete gene deletion collection of Schizo-
saccharomyces pombe strains for regulators of telomere
transcription, we isolated the putative ortholog of hMpn1
(SPAC23C11.10, herein referred to as mpn1+; the screening
will be presented elsewhere). mpn1D cells displayed higher
amounts of telomeric repeat-containing RNA (TERRA) (Azzalin
et al., 2007; Bah et al., 2012) and shorter telomeres compared
to wild-type (WT) strains (Figures S1A and S1B). In addition,856 Cell Reports 2, 855–865, October 25, 2012 ª2012 The Authorsmpn1D cells showed a mild slow-growth phenotype at the stan-
dard temperature of 30C. This phenotype was exacerbated in
the cold (20C), whereas mpn1D cells grew at rates similar to
WT at 36C (Figure 1A). Northern blot and RT-PCR analyses
revealed that mpn1+-deleted strains suffered a generalized
pre-mRNA splicing defect, as shown by the accumulation of
pre-mRNA transcripts comprising introns of different lengths
(TBP1, SPBC660.16, and DBP2; Figures S1C and S1D). The
spliceosome-dependent processing of the telomerase RNA
component Ter1 (Box et al., 2008) was also impaired, and
premature, catalytically inactive Ter1 accumulated in mpn1D
cells (Figure S1D). It is possible that the lack of complete Ter1
processing and the possible missplicing of pre-mRNAs coding
for other telomeric factors account for the aberrant telomere
length and TERRA accumulation observed in the deleted strains
(Figures S1A and S1B). Moreover, telomere-length abnormalities
appear not to be an evolutionarily conserved feature of Mpn1
deficiency, given that cells established from PN patients carry
telomeres of normal length (Walne et al., 2010). Nevertheless,
we do not exclude the possibility that mpn1+ deletion might
also affect telomere-length homeostasis and TERRA cellular
levels by processing RNAmolecules directly involved in telomere
maintenance.
We also tested for splicing of the U6 snRNA, which in fission
yeast comprises an intron of approximately 50 bases posttran-
scriptionally removed by the spliceosome (Tani and Ohshima,
1989). As for the other substrates, unspliced U6 accumulated
in mpn1D cells, and mature, spliced U6 was approximately
40% less abundant (Figures 1B, 2A, S1C andS1D). Total (spliced
plus unspliced) U6 transcripts in mpn1D cells were approxi-
mately 30% fewer than in WT cells, as judged by real-time quan-
titative RT-PCR (Figure 3A). On the contrary,mpn1+ deletion did
not substantially affect the total levels of 5S ribosomal RNA
(rRNA) and U5 spliceosomal snRNA (Figure 1B). Interestingly,
the splicing defects observed in mpn1+-deleted cells were
enhanced in the cold and partly resolved at 36C, at least in
terms of accumulation of spliced RNA species, as shown by
northern blot analysis, wherein 18S rRNA signals were used for
normalizing the ones from spliced mRNAs (Figure S1E). This
suggests that the growth defects associated with mpn1+ dele-
tion could be derived from improper pre-mRNA splicing.
Deletion ofmpn1+ Leads to Improper Processing of the
U6 30 End Oligo(U) Tail and Diminished Levels of U4/U6
di-snRNPs
High-resolution denaturing PAGE followed by northern blotting
with the use of U6 probes showed that mature U6 ran slower
in mpn1D cells (Figure 1B). We performed 30 rapid amplification
of complementary DNA (cDNA) ends (30 RACE) and found that
most U6 oligo(U) tracts contained five Us in WT and six Us in
mpn1D cells (Figure 1C). Moreover, inWT cells, the largemajority
of U6 snRNA terminated with a 30 end U containing a >p group; in
fact, treatment with polynucleotide kinase (PNK) in mild acidic
conditions (a treatment known to release terminal >p groups
from RNA molecules), but not with calf intestinal phosphatase
(CIP, which is unable to release >p groups), converted mature
U6 into a more slowly migrating form (Figure 1B) and rendered
it accessible to poly(A) polymerase (PAP)-mediated nucleotide
Figure 1. Cellular Consequences of mpn1+ Deletion
(A) Replicates of serial dilutions of the indicated yeasts were spotted on complete medium and grown at 20C, 30C, or 36C. Images were taken after 2 or 5 days
of incubation.
(B) Total RNAwas treated with T4 PNK inmild acidic conditions, CIP, or reaction buffer (buff) and separated in denaturing polyacrylamide gels. Mature U6, intron-
containing U6 (asterisk), U5 snRNA, and 5S rRNA were visualized via northern blotting. The position of a size marker of 150 bases is shown on the left.
(C) 30 RACE analysis of U6 oligo(U) tails. Bars and error bars are averages of the number of Us within U6 olgo(U) tails and SEM from three independent
experiments.
(D) Yeasts were grown at 20C, 30C, or 36C, and RNA was extracted and separated in nondenaturing conditions. The same membrane was hybridized
successively with U6, U4, and 5S oligonucleotides. U6/U4 di-snRNPs and free U6 and U4 are indicated. The arrowhead points to a slowly migrating U6 complex
of unknown origin that is devoid of U4molecules.Wells are indicated with ‘‘w’’. ‘‘U6denat’’ and ‘‘U4denat’’ indicate U6 andU4 detected in denaturing polyacrylamide
gels with the use of the same RNA prepared for di-snRNP analysis. Numbers on the right indicate the ratio between the U6/U4 di-snRNP signal and the 5S signal,
after normalization through the signal corresponding to mpn1+ cells grown at 30C.
See also Figures S1, S2, and S3.addition (Figure S2A). In contrast, inmpn1D cells, PNK treatment
did not affect the U6 run, nor was it needed to allow PAP-medi-
ated extension of U6 (Figures 1B and S2A). The electrophoretic
mobility of 5S rRNA and U5 snRNA remained unchanged in allFigure 2. Mpn1 Rescues the Cellular Defects of mpn1D Cells
(A) Northern blot analysis of U6 in the indicated yeast cells stably transformedwith
ratios between the signal associated with mature (M) and premature (P; unsplic
carrying ev.
(B) Splicing of the indicated transcripts was analyzed via northern blotting. Asteris
to mature and premature transcripts after normalization through mpn1+ ev samp
(C) Schematic representation of yeast Mpn1 proteins. Mpn1MUT carries histidine
(D) Replicates of serial dilutions of the indicated yeasts were spotted on comple
See also Figures S2 and S4.
Ctested conditions (Figure 1B). We conclude that, in mpn1+-
deleted cells, the U6 oligo(U) tails are longer than in normal cells
and terminate with an -OH group. The molecular defects that
accrue on U6 in mpn1D cells are not a secondary consequenceWTMpn1 or Mpn1MUT expression vectors or with control ev. Numbers indicate
ed) U6 after normalization through the U6 signal associated with mpn1+ cells
ks indicate pre-mRNAs. Numbers indicate ratios between the signal associated
les.
to alanine substitutions at the indicated positions.
te medium and grown at 20C or 30C.
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Figure 3. Enhanced U6 Expression Rescues the Cellular Defects of mpn1D Cells
(A) Northern blot analysis of U6 in strains stably transformedwith plasmids carrying one copy of U6 gene (snu6+) or with ev. Numbers at the bottom are normalized
ratios between mature and premature U6 signals (M/P), mature U6 and 5S signals (M/5S), and total (T) U6 and 18S rRNA, as measured by quantitative real-time
RT-PCR.
(B) Splicing of the indicated transcripts was analyzed via northern blotting (upper panels) and RT-PCR (lower panels). Asterisks indicate pre-mRNAs. Numbers
below northern blots (upper panels) are as in Figure 2B. For TBP1 RT-PCR, primer pairs spanning the third intron (INTR3) were used. Intronless act1+ mRNA was
amplified to control for loading. RT, reverse transcription.
(C) Analysis of U4/U6 di-snRNP levels in the indicated strains. Numbers and labeling are as in Figure 1D.
(D) Replicates of serial dilutions of the indicated yeasts were spotted on complete medium and grown at 20C or 30C.
See also Figure S2.of impaired pre-mRNA splicing, because strains in which the
unrelated splicing factor Prp1 (Potashkin et al., 1989) was
inhibited showed severely compromised global splicing (Fig-
ure S3A), and yet U6 RNA, although present at low levels, ran
normally in polyacrylamide gels (Figure S3B). Analysis of U4/
U6 di-snRNPs in native polyacrylamide gels revealed that free
U4 accumulated in mpn1D cells at standard temperatures,
whereas the levels of U4/U6 di-snRNPs diminished to extents
similar to the ones measured for mature U6 snRNA (Figures 1D
and 2A). The levels of di-snRNPs were further diminished at
20C and were augmented at 36C (Figure 1D). These data
strongly indicate that in absence of Mpn1, lower levels of U6
are available for di-snRNP complex assembly, thereby leading
to the accumulation of free U4, lower U4/U6 di-snRNP levels,
and, most likely, inefficient pre-mRNA splicing.
The Integrity of the Tetrapeptide Motifs of Mpn1
Is Essential for Its Function In Vivo
We generated mpn1+ and mpn1D strains overexpressing
C-terminally myc-tagged, WT Mpn1. Ectopic Mpn1 expression
in mpn1D cells rescued U6 aberrations, pre-mRNA splicing
defects, and slow growth in the cold, but did not affect any of
these characteristics in WT cells (Figures 2A–2D). Thus, the
above-described phenotypes are true outcomes ofmpn1+ dele-
tion. We also generated strains expressing a myc-tagged variant
of Mpn1 (Mpn1MUT) wherein the two putative catalytic histidines
within its tetrapeptide motifs (H109 and H199) are mutagenized
into alanines (Figure 2C). Mpn1MUT was unable to restore normal
U6 processing and further impaired pre-mRNA splicing and cell
growth in the cold when overexpressed in mpn1D cells (Figures
2A–2D), indicating that H109 and H199 are essential for Mpn1858 Cell Reports 2, 855–865, October 25, 2012 ª2012 The Authorsfunction in vivo. Mpn1 and Mpn1MUT were expressed at compa-
rable levels in WT and mpn1D cells (Figure S4A), excluding the
possibility that the inability ofMpn1MUT to rescue the phenotypes
associated with the deletion of mpn1+ was due to insufficient
protein expression. Both ectopically expressed Mpn1 variants
coimmunoprecipitated with U6 RNA, but not with 5S rRNA, in
immunoprecipitation (IP) experiments with myc antibodies
(Figure S4A). This suggests that Mpn1 interacts, directly or indi-
rectly, with U6 in vivo independently of H109 and H199. The
ability of Mpn1 to interact with U6 is further supported by the
observation that myc-tagged Mpn1 expressed from its endoge-
nous promoter localizes mainly to the nucleus (Figure S4F).
The Pre-mRNA Splicing Defects inmpn1D Cells Are
Compensated by Overexpression of U6
In order to restore normal U6 levels inmpn1D cells, we generated
strains carrying one additional copy of the U6 gene (snu6+) stably
integrated at the aur1+ locus. Compared to WT strains carrying
empty vector plasmids (ev), the levels of total U6 (spliced plus
unspliced) increased 1.6-fold and 1.1-fold in mpn1+ and
mpn1D cells, respectively, with extra snu6 (Figure 3A). U6 mole-
cules remained longer inmpn1D:snu6 cells than in WT cells and
were devoid of terminal >p groups, whereas the defects in
splicing and in U4/U6 di-snRNP cellular levels were essentially
resolved (Figures 3A–3C and S2B). Expression of an intronless
U6 gene stably integrated at the aur1+ locus also restored the
splicing defects in mpn1D, whereas it did not affect splicing in
WT strains (data not shown). Importantly, the slow-growth
phenotype induced by cold temperature was also rescued by
snu6+ expression (Figure 3D). Therefore, additional newly tran-
scribed U6 can compensate for the splicing defects associated
Figure 4. Conservation of Function among Yeast and Human Mpn1 Proteins
(A) Northern blot analysis of U6 in RNA prepared from lymphoblasts established from two independent PN patients (P1 and P2), the healthy brother of P1 (R1), and
an unrelated healthy donor (ctrl). Numbers at the bottom are normalized ratios between total U6 and 18S rRNA, as measured by quantitative real-time RT-PCR.
(B) 30 RACE analysis of U6 oligo(U) tails in R1 and P1 cells. Bars and error bars are averages of the number of Us within U6 oligo(U) tails and SEM from two
independent experiments.
(C) Schematic representation of human Mpn1 proteins. In hMpn1P1, protein conservation is lost at position 168 (OOF: out of frame). hMpn1MUT carries histidine-
to-alanine substitutions at the indicated positions.
(D) Northern blot analysis of U6 30 end processing in the indicated yeast strains transformed with plasmids expressing hMpn1 variants. Asterisks indicate intron-
containing RNAs.
(E) Replicates of serial dilutions of the indicated yeasts were spotted on complete medium and grown at 20C or 30C.
See also Figures S4 and S5.with mpn1+ deletion, indicating that pre-mRNA splicing in
mpn1D cells is largely derived from the diminished levels of
cellular U6. These observations also further support the notion
that the retarded growth of mpn1D cells is attributable to ineffi-
cient splicing.
hMpn1 Is a Functional Ortholog of Mpn1
We prepared total RNA from two unrelated lymphoblastoid cell
lines established from two patients affected by PN (hereafter,
P1 and P2; Figure 4A) and from two control cell lines established
from an unrelated healthy individual (ctrl) and from a healthy
brother of P1 (relative 1: R1) (Volpi et al., 2010). Total U6 levels
were similar in the four cell lines, whereas the U6 snRNA electro-
phoretic run was retarded in both P1 and P2 compared to the
two control samples (Figure 4A). Most U6 molecules from R1
terminated with an oligo(U) tract comprising five Us and refrac-
tory to PAP-mediated nucleotide elongation in the absence of
PNK treatment; in contrast, the majority of U6 transcripts in P1
terminated with six to nine Us and were largely elongated by
PAP to similar extents in PNK-treated and PNK-untreated
samples (Figures 4B and S2C). Thus, hMpn1 deficiency leads
to aberrant U6 processing, similar to what was observed in yeast
cells. Deep sequencing of the entire poly(A)+ transcriptome of
R1, P1, and P2 cell lines and RT-PCR analysis of the two
randomly chosen RAD9A and CYC1 gene transcripts did notCreveal any obvious accumulation of intron-containing pre-
mRNAs in PN cells, indicating that these particular cell lines do
not suffer from a generalized splicing defect (Figures S5A
and S5B).
Next, we generated yeast expression vectors carrying alleles
of hMpn1 corresponding toWT hMpn1, tomutant hMpn1 carried
by P1 (hMpn1P1 in Figure 4C), and to hMpn1 carrying two histi-
dine-to-alanine substitutions in its tetrapeptide motifs (H120
and H208; hMpn1MUT in Figure 4C). The WT hMpn1 completely
rescued the defects in U6 processing, pre-mRNA splicing, and
growth in the cold when expressed in mpn1D yeast cells, but it
did not affect any of these parameters in WT yeast cells (Figures
4D and 4E). In contrast, hMpn1P1 and hMpn1MUT were unable to
restore U6 processing in mpn1D cells and further exacerbated
the accumulation of unspliced pre-mRNAs and slow growth in
the cold (Figures 4D and 4E). All hMpn1 proteins were expressed
at similar levels in all yeast cells whether deficient in Mpn1 or not
(Figure S4B).
hMpn1 Physically Interacts with the NTC Complex
Wegenerated different human immortal cell lines stably express-
ing strep-HA-tagged hMpn1 (hMpn1-SHA). hMpn1-SHA local-
ized predominantly to the nucleus in HeLa cells, as shown by
indirect immunofluorescence (Figure S4G), and copurified with
U6 snRNA in streptavidin-purification experiments performedell Reports 2, 855–865, October 25, 2012 ª2012 The Authors 859
Figure 5. Analysis of hMpn1 Activity In Vitro
(A) Recombinant hMpn1 or hMpn1MUT were incubated with the indicated RNA oligonucleotide substrates, mimicking the structured U6 snRNA 30 terminus, for
1 hr. As a control, reactions were also performed with buffer only (-) or with empty vector (ev) purifications. RNA products were resolved in denaturing poly-
acrylamide gels.
(B) hMpn1 was incubated with analogous RNA and DNA substrates for 1 hr.
(C) 6Us RNA substrate was 50-end radioactively labeled and incubated with hMpn1 for 1 hr. Reaction products were separated as above, and radioactive signal
was detected.
(D) The indicated substrates were treated with recombinant hMpn1 in the presence or absence of 20 mM EDTA for 1 hr.
(E) The indicated substrates were incubated with hMpn1, and reaction aliquots were taken at the indicated time points. The graph shows quantifications of the
signals at each time point after setting to 1 the value corresponding to the sum of substrates and products measured for the first time point.
(F) 7Us RNA substrate was incubated with hMpn1 for 60min or 0.2 min, and reaction products were treated with PNK in mild acidic conditions or with CIP prior to
gel electrophoresis.
(G) Schematic representation of Mpn1 enzymatic activity in vitro. In all panels, ‘‘m’’ indicates the mix of the four RNA substrates used as a molecular-weight
marker.
See also Figure S6.with the use of hMpn1-SHA-expressing HEK293T cells (Fig-
ure S4C). Fractions containing hMpn1-SHA were also strongly
enriched in U5 snRNA, but not in U1 and U4 snRNAs or tRNAGlu
(Figure S4C). Moreover, mass spectrometric analysis of the
same purification samples revealed the presence of PRP19,
CDC5L, and PLRG1 polypeptides, which are core components
of the human NTC (Figure S4D). The physical interaction
between hMpn1-SHA and NTC members was further confirmed
with antibodies for human PRP19, CDC5L, and PLRG1 (Fig-
ure S4E). These data are consistent with high-throughput in-
teraction experiments indicating that the putative budding yeast
and Drosophila melanogaster orthologs of Mpn1 (Usb1/
YLR132C and CG167090, respectively) physically interact with
Prp19 proteins (Giot et al., 2003; Hazbun et al., 2003; Krogan
et al., 2006; Yu et al., 2008). Altogether, these results imply
that Mpn1 and hMpn1 are functional orthologs promoting U6
processing in distantly related eukaryotes. In addition, the
enrichment of U5 snRNA in hMpn1 purification fractions
suggests that hMpn1 might be a novel component of the 35S
U5 snRNP, which has been shown to contain NTC factors
(Makarov et al., 2002; Makarova et al., 2004).860 Cell Reports 2, 855–865, October 25, 2012 ª2012 The AuthorshMpn1 Is a 30-to-50 RNA Exonuclease that Processes U6
Oligo(U) Tails In Vitro
To test the putative enzymatic activity of Mpn1 proteins, we puri-
fied recombinant, C-terminally histidine-tagged hMpn1 and
hMpn1MUT expressed in bacteria (Figure S6A). We incubated
the recombinant proteins with RNA oligonucleotides mimicking
the structured 30 end of free human U6 (Rinke et al., 1985), termi-
natingwith four to sevenUs (substrates: 4Us, 5Us, 6Us, and 7Us,
respectively). Due to self-annealing, the four different substrates
are expected to generate hairpin structures with stems exposing
zero, one, two, or three Us, respectively (Figure 5A). Upon incu-
bation with hMpn1, all substrates were processed into a ladder
of shorter species differing from each other by one nucleotide;
no oligonucleotide substrate was processed by mock purifica-
tion extracts or hMpn1MUT (Figure 5A). Thus, hMpn1 shows
ribonuclease (RNase) activity that depends on the two histidines
within its tetrapeptide motifs. Recombinant hMpn1, but not
hMpn1MUT, processed shorter 6Us RNA oligonucleotides that
were unable to form secondary structures (linear 6Us: 6UsLIN)
mainly into 5Us oligonucleotides (Figure S6B), as observed for
structured 6Us. This indicates that the number of Us within the
oligo(U) tract, not its secondary structure, regulates hMpn1
nuclease activity. hMpn1 did not process analogous DNA oligo-
nucleotides terminating with six or seven thymines (substrates:
6Ts and 7Ts, respectively; Figure 5B), revealing hMpn1 speci-
ficity for RNA. hMpn1-dependent processing was executed in
a 30-to-50 direction, as revealed by reactions performed using
6Us oligonucleotides radioactively labeled at their 50 end (Fig-
ure 5C). hMpn1 actively processed RNA substrates in the
absence of ATP andmetal ions and under different pH conditions
(Figure S6C). The addition of EDTA to the reaction did not block
hMpn1 activity, although 6Us and 7Us were processed only into
5Us, whereas 5Us and 4Us were very poorly processed (Figures
5D, S6B, and S6C). This suggests that hMpn1 shows a prefer-
ence for substrates terminating with six or seven Us. Consis-
tently, time-course experiments clearly showed that 6Us and
7Us are quickly trimmed to 5Us within the first few minutes of
the reaction (Figures 5E and S6B). Finally, we noticed that
hMpn1-processed products ran faster than synthesized oligonu-
cleotides of the same length containing terminal -OH groups,
possibly due to the presence of a phosphate group at the 30
end of hMpn1 products (Figures 5A–5E). Treatment with PNK
under mild acidic conditions, but not with CIP, converted
hMpn1 products into more slowly migrating forms, indicating
that hMpn1 products terminate with a 30 >p group (Figure 5F).
The observations that Mpn1 exonucleolitic activity gener-
ates >p groups and is not fully inhibited in the presence of
EDTA suggest that Mpn1 could be a metal-ion-independent
RNase, although additional experiments are needed to confirm
this supposition. Moreover, the presence of a terminal >p group
did not affect the ability of hMpn1 to quickly process 6Us >p
(produced from processing of 7Us-OH substrates) into 5Us >p,
whereas both 5Us >p and 5Us-OH were processed with slow
kinetics (Figure 5E). Thus, hMpn1 processes oligo(U) terminating
with >p or -OH groups with similar efficiencies. In summary,
hMpn1 is a 30-to-50 RNA exonuclease that is able to trim U6
oligo(U) tails into shorter tracts terminating with 30 end >p groups
(Figure 5G). This is highly consistent with the U6 snRNA molec-
ular defects in PN cells, wherein we observe accumulation of
U6 molecules terminating with 6Us-OH or 7Us-OH, which corre-
spond to efficient substrates for hMpn1 in vitro (Figures 4A
and 4B). The ability of hMpn1 to rescue the U6-processing
defects of mpn1D yeasts (Figure 4D) indicates that human and
fission yeast Mpn1 proteins share the same catalytic activity.
Mpn1 Sustains U6 Stability
The diminished U6 cellular levels in mpn1D yeast cells and the
altered chemical composition of U6 oligo(U) tracts in Mpn1-
deficient yeast and human cells suggest the possibility that the
stability of U6 molecules could be altered. We measured the
degradation rates of yeast U6 transcripts by inhibiting RNAPIII
with the specific inhibitor ML-60218 (Wu et al., 2003) in WT
and mpn1D yeast cells over the course of 12 hr. To monitor the
degradation of similar starting amounts of U6 molecules, we
also included in the same set of experiments mpn1D cells
carrying one additional copy of the U6 gene (mpn1D:snU6). In
WT cells, U6 levels declined linearly throughout the time period
and were reduced to approximately 60% of the starting amount
of U6 by the end of the experiment (Figures 6A and 6C). In bothCmpn1+-deleted strains, U6 levels dropped precipitously during
the first 3 hr to approximately 40% and then slowly decreased
further to 30% during the remaining 9 hr (Figures 6A and 6C).
The long-lived 5S small RNA was stable during the entire time
period, whereas leucine tRNA decayed similarly in both normal
and mpn1+-deficient cells (Figure 6A). In accordance with the
increased degradation rates of U6, mpn1D and mpn1D:snu6
cells were more sensitive than WT cells when grown in medium
containing ML-60218 (data not shown).
An analogous situation was observed in human cells treated
with actinomycin D for inhibition of global transcription over
12 hr. U6 transcripts declined with fairly linear kinetics in healthy
R1 lymphoblasts and had a calculated half-life of approximately
4.7 hr (Figures 6B and 6C). In PN-affected P1 and P2 cells, U6
decay was faster, especially during the first 3 hr of treatment.
The U6 half-life was approximately 1.7 hr in P1 cells and 2.8 hr
in P2 cells (Figures 6B and 6C). As for yeast cells, 5S RNA
steady-state levels remained constant during the time course
in the three cell lines (Figure 6B). Altogether, these observations
indicate that U6 transcripts are less stable in Mpn1-deficient
yeast and human cells and suggest that Mpn1-mediated pro-
cessing of U6 oligo(U) tails prevents U6 snRNA degradation.
DISCUSSION
We have demonstrated here that U6 molecules that fail to be
posttranscriptionally modified by Mpn1 are rapidly directed
toward degradation, thereby establishing Mpn1 as a regulator
of U6 stability (Figure 6D). Similar conclusions have been
recently reached for Usb1p, the Saccharomyces cerevisiae
ortholog of Mpn1, further supporting the evolutionary conserva-
tion of Mpn1-associated functions (Mroczek et al., 2012).
Extending beyond this notion, we have also shown that Mpn1
is an actual RNA exonuclease and that the stability of U6 mole-
cules is compromised in lymphoblastoid cells established from
patients affected by PN. It is now necessary to understand the
details of themolecularmechanisms throughwhichMpn1 antag-
onizes U6 degradation. In vitro experiments have clearly shown
that the presence of a terminal >p group on U6 enhances its
affinity for the LSm2–8 complex and inversely reduces La protein
binding (Licht et al., 2008). Therefore, it is conceivable that
binding of the LSm2–8 complex stabilizes U6 by hiding its 30
end from degradation machineries. Still, a more direct func-
tion could also be envisaged for the >p group. A fraction of
Drosophila melanogaster and budding yeast U6 snRNA was
reported to be 30 polyadenylated by the noncanonical PAP
Trf4, and thus directed toward degradation through the nuclear
exosome (Nakamura et al., 2008; Wyers et al., 2005). A similar
mechanism might also exist in humans, given that a small frac-
tion of U6molecules fromHeLa cells contain a posttranscription-
ally added adenylic acid residue at their 30 ends (Chen et al.,
2000; Sinha et al., 1998). Because Trf4 requires a free 30-OH
terminal group for it to be able to add nucleotides, the presence
of a terminal >p group on U6 is expected to physically hinder
Trf4-mediated polyadenylation. Regardless of the actual molec-
ular mechanism through which Mpn1 protects U6 from degrada-
tion, our results suggest the existence of a thus far unappreci-
ated quality-control pathway, perhaps coupled with pre-mRNAell Reports 2, 855–865, October 25, 2012 ª2012 The Authors 861
Figure 6. Reduced Stability of U6 snRNA in
Human and Yeast Mpn1-Deficient Cells
(A) The indicated yeast cells were treated with
ML-60218 for a total of 12 hr, and RNA samples
were prepared every 3 hr. RNA was subjected to
northern blot analysis. Asterisks indicate prema-
ture U6 and putative products generated by
RNAPIII premature termination. U6 deg, putative
degradation products of U6; tRNALeu, leucine
tRNA.
(B) R1, P1, and P2 lymphoblasts were treated with
actinomycin D (ACTD) for 12 hr. RNA samples
were prepared every 3 hr and processed via
northern blotting for detection of U6 and 5S RNAs.
Calculated half-lives (t1/2) of U6 are indicated for
the different cell lines.
(C) Quantification of U6 RNA levels in yeast (upper
graph) and human (lower graph) cells upon tran-
scription inhibition. For each sample, U6 signals
were normalized through the corresponding 5S
signals and successively expressed as fold
decrease over U6 signal at time 0. Values and error
bars are means and SEM from three to five inde-
pendent experiments.
(D) Model depicting Mpn1-associated functions in
U6 processing and stabilization. See Discussion
for details.splicing, that may decide whether or not specific U6 molecules
need to be eliminated from the cell (Figure 6D).
By showing thatMpn1 is the 30-to-50 exonuclease that trimsU6
30 end oligo(U) tails, we have also revealed the identity of the
enzyme that counteracts TUTase in vivo. Our data indicate that
Mpn1 alone is sufficient not only to restrict U6 oligo(U) tails but
also to introduce the >p group found on the large majority of
cellular U6 (Figure 6D). The point at which Mpn1 accesses and
modifies U6 remains to be determined. However, the evolution-
arily conserved physical interaction of Mpn1 with the spliceo-
some-associated NTC complex suggests that Mpn1 could
modify U6 within the active spliceosome upon NTC-mediated
recruitment to the 35S U5 snRNP (Makarov et al., 2002;
Makarova et al., 2004) (Figure 6D). This idea is consistent with
experiments performed with the use of HeLa nuclear extracts
showing that long U6 molecules terminating with -OH groups
can enter the spliceosome and that some of these shorten with
time as splicing proceeds (Tazi et al., 1993).
It has been proved that diminished expression or deletion of
several yeast NTC proteins results in reduced recycling of U6
molecules upon splicing completion and consequent accumula-
tion of free U4 (Chen et al., 2006; Lygerou et al., 1999). Although
the lower levels of cellular U6 present in mpn1D cells are per se
sufficient to explain the diminished levels of U4/U6 di-snRNPs
and the inefficient pre-mRNA splicing, the observations just
mentioned suggest that U6 recycling might also be impaired in
Mpn1-deficient cells and that the recycling defects observed
in NTC mutants might stem, at least in part, from a lack of862 Cell Reports 2, 855–865, October 25, 2012 ª2012 The AuthorsMpn1-mediated processing of U6.
Intriguingly, the LSm2–8 ring promotes
U6 recycling through the recruitment ofthe U4/U6 annealing factor Prp24/p110 (Bell et al., 2002;
Martin-Tumasz et al., 2011; Pannone et al., 1998; Raghunathan
and Guthrie, 1998; Ryan et al., 2002). These observations,
together with the already-mentioned notion that a terminal >p
group on U6 augments its affinity for the LSm2–8 complex (Licht
et al., 2008), make it tempting to speculate that Mpn1 enzymatic
activity could promote U6 recycling by allowing LSm2–8 and
Prp24/p100 binding to U6.
Our work also provides a framework in which to better under-
stand the pathogenesis of PN. Although the accumulation of
intron-containing pre-mRNA molecules in mpn1D yeasts
suggests that inefficient splicing could be the molecular trigger
of PN, the lack of a generalized splicing defect observed in PN
lymphoblasts seems to contradict this hypothesis. Still, it is
possible that Mpn1 deficiency can be better tolerated in human
cells than in yeasts due to higher U6 cellular levels. Indeed, the
human genome possesses at least five transcriptionally active
U6 snRNA genes (Domitrovich and Kunkel, 2003), and we have
clearly shown that insertion of one extra copy of the U6 gene in
mpn1D cells is sufficient to avert splicing defects. Hence, pre-
mRNA splicing could be affected only in cell types wherein U6
cellular levels are limiting. For example, U6 transcripts are down-
regulated in rat bone marrow cells during development (Ray
et al., 1997). Similarly, exogenous insults such as UV light irradi-
ation are known to reduce U6 steady-state levels (Choudhury
et al., 1988); interestingly, in this regard, some PN patients
have been diagnosed with light sensitivity of the skin (Arnold
et al., 2010). Therefore, Mpn1 deficiency might have a different
impact on the cell according to the tissue- and developmental-
stage-specific expression of U6 snRNA, as well as the environ-
mental conditions. This hypothesis could explain why only
a limited number of tissues are affected in PN patients (Colombo
et al., 2012). An alternative but not mutually exclusive hypothesis
is that Mpn1 might modify RNA substrates other than U6 snRNA
to possibly regulate their stability. Compromised metabolism of
these yet-to-be-discovered RNAs might be responsible for PN
pathogenesis. As with our PN cells, mouse embryonic fibro-
blasts knocked out for the NTC member PLRG1 also failed to
show a generalized splicing defect (Kleinridders et al., 2009).
Moreover, members of the mammalian NTC complex have
been implicated in several nonsplicing mechanisms, including
cellular senescence, the DNA damage response, and interstrand
crosslink repair (Legerski, 2009). Mpn1 and other members of
the NTC complex could cooperatively regulate the stability of
ncRNA species involved in these different cellular pathways,
thus explaining the pleiotropism of PN.
EXPERIMENTAL PROCEDURES
Yeast Strains
Original Schizosaccharomyces pombe strains were kind gifts of J. P. Cooper
and R. Allshire or were purchased from Bioneer (see Table S1). Where indi-
cated, yeast strains were transformed with pCST159-derived plasmids in
order to obtain stable integrants upon Aureobasidin selection.
Human Cell Lines
Lymphoblastoid cell lines were obtained from Lidia Larizza (University of
Milano, Italy), Galliera Genetic Bank (Genova, Italy), and Alessandra Renieri
(University of Siena, Italy). ML07136M (P1 in the text) and RT1 (P2) are
SV40-immortalized lymphoblastoid cell lines derived from two independent
PN patients, and GGB04410M (R1) is derived from a healthy brother of P1
(Volpi et al., 2010). MR140 (ctrl) is an SV40-immortalized lymphoblastoid cell
line derived from a completely unrelated healthy individual. To generate stable
cell lines expressing hMpn1, we transduced HEK293T and HeLa cells with
retroviruses expressing strep-HA-tagged hMpn1 (pBABE-Hygro-hMpn1) or
with empty vector control retroviruses.
RNA Extraction and Analysis
Total yeast RNA was extracted with the use of hot phenol according to stan-
dard procedures. Total human RNA was prepared with TRIzol (Invitrogen)
followed by column purification with the Direct-zol kit (Zymo Research).
RNA was subjected to DNase I digestion at least once before further proce-
dures. To remove 30 terminal phosphate groups from RNA, we used T4 PNK
(New England BioLabs [NEB]) following published protocols (Schu¨rer et al.,
2002). CIP (NEB) treatment was performed according to the manufacturer’s
instructions. For native PAGE, RNA was extracted with cold phenol and
resolved in a 5% nondenaturing polyacrylamide-Tris-borate-EDTA gel. For
30 RACE experiments, we used PNK- and PAP-treated total RNA and the
FirstChoice RLM-RACE kit (Ambion) according to the manufacturer’s
instructions. RNA-seq was performed on poly(A)+ RNA purified with the
TrueSeq SBS RNA kit v5 (Illumina) with the use of the Illumina HiSeq 2000
platform at FASTERIS (Plan-les-Ouates, Switzerland).
Mpn1 Nuclease Assay
Recombinant hMpn1 proteins were purified with the HisPur Cobalt Resin
(Thermo Scientific) according to the manufacturer’s instructions. RNA and
DNA oligonucleotide substrates were synthesized and gel-purified at Micro-
synth AG (Balgach, Switzerland). Oligonucleotide substrates (see Table S2)
were mixed in 20 mM Tris-HCl (pH 7.4), 100 mM NaCl, and 0.005% Tween
20. The mixture was incubated at 65C for 5 min, cooled down to 37C at
a rate of 0.05C/s, and quickly passed to ice. After the addition of 1 ml of
recombinant hMpn1 (36 pmol/ml), reactions were incubated for the indicatedCtime at 37C. Reactions were stopped via the addition of equal volumes of
electrophoresis loading buffer containing 8 M urea and incubation at 90C
for 5 min. Samples were loaded directly in denaturing polyacrylamide gels.
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Raw sequencing data for the transcriptome of lymphoblastoid cell lines have
been deposited in the ArrayExpress database under accession number
E-MTAB-1197 (http://www.ebi.ac.uk/arrayexpress/).
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